• The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of several hundred strains monthly;
  • Bpifrance paid €1.5m to DEINOVE as part of the first milestone payment of the AGIR Programme.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has successfully completed the first key milestone of the AGIR program - Antibiotics against Resistant Infectious Germs - which is supported by the Investments for the Future Program. This milestone triggered the payment of €1.5m.

The AGIR program aims to explore the antimicrobial potential of rare bacterial strains with the objective of identifying new antibiotic structures and developing innovative treatments to address the health challenge of increasing antimicrobial resistance. 

The goal for DEINOVE is to accelerate the screening of antibiotic activities of multiple strains under various conditions in order to quickly detect new antimicrobial structures. The first stage of the AGIR program led to the development of a robotic platform for extracting and screening strains. The high-tech equipment has been consolidated and the experimental protocols validated. 

"With our robotic platform, we now have a unique tool to explore the potential of many rare microorganisms, both from our proprietary library, our targeted collection activities, and samples provided by our research partners [1]. First bacterial extracts of interest have been identified and are currently being dereplicated [2], in order to identify the molecule that is causing the antibiotic activity and verify its innovative character. We want to move fast because antibiotic resistance is progressing rapidly throughout the world and represents a major danger to mankind with projections on deaths amounting to 10 million from 2050 onwards [3] ," says Georges GAUDRIAULT, Scientific Director of DEINOVE.

The division Next-generation anti-infectives which is one of DEINOVE's strategic pillars was initially developed by DEINOBIOTICS, a subsidiary wholly-owned by DEINOVE. A decision was taken to merger DEINOBIOTICS into DEINOVE through a total asset transfer on November 1, 2018, after whichDEINOBIOTICS was removed from the Trade and Companies Register.


[1] DEINOVE has initiated research collaborations with the Italian biotech company Naicons and the diagnostic specialist bioMérieux, which provide the Company with a range of diverse strains. Other partnerships of this nature are under discussion.

[2] Analytical process of an active mixture to discard known substances

[3] https://www.bbc.com/news/health-30416844